This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Behavioral Effects of Pregabalin and Cannabis

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Joshua A. Lile, Ph.D., University of Kentucky
Information provided by (Responsible Party):
Joshua A. Lile, Ph.D., University of Kentucky Identifier:
First received: January 9, 2012
Last updated: May 1, 2017
Last verified: May 2017
Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.

Condition Intervention Phase
Cannabis-use Disorders Drug: Pregabalin Drug: Placebo Early Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Behavioral Effects of Drugs (Outpatient)(43)

Resource links provided by NLM:

Further study details as provided by Joshua A. Lile, Ph.D., University of Kentucky:

Primary Outcome Measures:
  • number of self-administered puffs of smoked cannabis containing active THC concentrations compared to placebo under controlled laboratory conditions [ Time Frame: 22 days ]

Estimated Enrollment: 13
Actual Study Start Date: February 1, 2017
Estimated Study Completion Date: December 31, 2019
Estimated Primary Completion Date: June 30, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pregabalin 1
Dose 1
Drug: Pregabalin
pregabalin 2x daily for duration of study
Placebo Comparator: Placebo
Drug: Placebo
placebo 2x daily for duration of study


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • regular cannabis use
  • good health other than cannabis use
  • willingness to attempt abstinence
  • effective form of birth control in female subjects
  • available for up to 6 hrs every day for two 2-week test periods with an intervening break of 10 days each
  • located in close proximity to University of Kentucky

Exclusion Criteria:

  • medical screening outcomes outside normal ranges or deemed clinical insignificant
  • medical history that would contraindicate pregabalin administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01511640

United States, Kentucky
Laboratory of Human Behavioral Pharmacology Recruiting
Lexington, Kentucky, United States, 40536-0086
Contact: Frances Wagner, RN    859-257-5388   
Principal Investigator: Joshua A. Lile, Ph.D.         
Sponsors and Collaborators
Joshua A. Lile, Ph.D.
Principal Investigator: Joshua A. Lile, Ph.D. University of Kentucky
  More Information

Responsible Party: Joshua A. Lile, Ph.D., Associate Professor of Behavioral Science, University of Kentucky Identifier: NCT01511640     History of Changes
Other Study ID Numbers: R01DA036550 ( U.S. NIH Grant/Contract )
Study First Received: January 9, 2012
Last Updated: May 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Joshua A. Lile, Ph.D., University of Kentucky:

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on September 21, 2017